Alzheimer's Disease Trial, Recruiting NCT06618872 Sponsor: University Hospital, Geneva Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06618872
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to participate
  • People between 50 and 85 years of age
  • People who have been diagnosed with Mild Cognitive Impairment (some memory or thinking test results outside the normal range, but still able to manage daily activities) or mild dementia (difficulties with both thinking and daily activities)
  • People who have had an MRI brain scan within the 6 months before the screening visit
  • People for whom a doctor has ordered an amyloid PET scan (a brain imaging test that looks for a specific protein linked to Alzheimer's disease)
  • People who are able and willing to follow the study requirements, as determined by the study investigator

Who may not be able to join:

  • People who have a psychiatric disorder, significant white matter changes in the brain, or signs of a type of dementia caused by blood vessel problems
  • People whose vision or hearing is not adequate for completing memory and thinking tests
  • People who have previously taken part in a clinical trial for Alzheimer's disease that may have affected certain proteins in the brain
  • People currently enrolled in other trials or studies that are not compatible with this study's brain imaging procedures (confirm with trial site)
  • People who have metal implants or devices in their body that make MRI scanning unsafe
  • Women who could become pregnant must not be pregnant (confirmed by a urine test on the day of imaging) or breastfeeding at the time of screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +41223727252

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Geneva
Registry
ClinicalTrials.gov
Start date
3 December 2024
Est. completion
30 August 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Difference between tau-PET with [18F]RO948 and amyloid PET in the change of physician's diagnostic confidence (50-100% visual analogue scale) across time; Difference between tau-PET with [18F]RO948 and amyloid PET in the changes in etiological diagnoses across time (i.e., from Alzheimer disease (AD) to non-AD, or from non-AD to AD).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov